Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

NIKUNJ N SHAH

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1134109861
CMS profile
6048
Location
CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,025.17

5 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $686.05 2
Food and Beverage $339.12 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $876.05 3
Allergan Inc. $114.09 1
Alnylam Pharmaceuticals Inc. $35.03 1

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

NIKUNJ N SHAH

NPI 1134109861 · CMS profile ID 6048

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

CHICAGO, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
NIKUNJ N SHAH, NPI 1134109861, CMS profile ID 6048. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). NIKUNJ N SHAH, NPI 1134109861, CMS profile ID 6048. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
NIKUNJ N SHAH, NPI 1134109861, CMS profile ID 6048, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–5 of 5 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1134109861?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

5 matching records · $1,025.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 5 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–5 of 5.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alnylam Pharmaceuticals Inc. $35.0311/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701568981 CMS
Celgene Corporation $508.6009/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672926803 CMS
Celgene Corporation $177.4509/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672969019 CMS
Celgene Corporation $190.0009/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672969105 CMS
Allergan Inc. $114.0904/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671120865 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,025.17 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $14,196.00 2
PY2023 Principal investigator $4,123.60 1
PY2022 Recipient $1,050.00 1
PY2022 Principal investigator $50,173.36 7
PY2021 Principal investigator $109,994.91 66
PY2020 Principal investigator $59,082.50 29
PY2019 Recipient $1,564.98 10
PY2019 Principal investigator $89,350.75 25

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

66 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $1,459.00 12/22/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522307
Principal investigator 1 Allergan, Inc. $975.00 12/01/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001889
Principal investigator 1 Allergan, Inc. $390.00 12/01/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001891
Principal investigator 1 Allergan, Inc. $1,950.00 12/01/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001893
Principal investigator 1 Allergan, Inc. $975.00 12/01/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001895
Principal investigator 1 PFIZER INC. $1,014.00 11/24/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832792159
Principal investigator 1 Allergan, Inc. $1,417.66 11/19/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001887
Principal investigator 1 Gilead Sciences, Inc. $777.00 10/20/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522305
Principal investigator 1 Gilead Sciences, Inc. $975.00 10/18/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522303
Principal investigator 1 Allergan, Inc. $300.00 10/07/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001883
Principal investigator 1 Allergan, Inc. $2,090.00 10/07/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001885
Principal investigator 1 Gilead Sciences, Inc. $1,459.00 09/22/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522301
Principal investigator 1 PFIZER INC. $7,215.00 09/22/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832804677
Principal investigator 1 Allergan, Inc. $171.00 09/15/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001881
Principal investigator 1 Allergan, Inc. $150.00 09/14/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001873
Principal investigator 1 Allergan, Inc. $150.00 09/14/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001875
Principal investigator 1 Allergan, Inc. $342.00 09/14/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001877
Principal investigator 1 Allergan, Inc. $1,350.00 09/14/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001879
Principal investigator 1 Allergan, Inc. $338.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001847
Principal investigator 1 Allergan, Inc. $150.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001849
Principal investigator 1 Allergan, Inc. $171.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001851
Principal investigator 1 Allergan, Inc. $650.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001853
Principal investigator 1 Allergan, Inc. $650.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001855
Principal investigator 1 Allergan, Inc. $42.25 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001857
Principal investigator 1 Allergan, Inc. $171.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001859
Principal investigator 1 Allergan, Inc. $400.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001861
Principal investigator 1 Allergan, Inc. $42.25 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001863
Principal investigator 1 Allergan, Inc. $975.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001865
Principal investigator 1 Allergan, Inc. $42.25 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001867
Principal investigator 1 Allergan, Inc. $42.25 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001869
Principal investigator 1 Allergan, Inc. $150.00 09/13/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001871
Principal investigator 1 Allergan, Inc. $650.00 08/03/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001843
Principal investigator 1 Allergan, Inc. $650.00 08/03/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001845
Principal investigator 1 Gilead Sciences, Inc. $378.00 07/21/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522299
Principal investigator 1 Gilead Sciences, Inc. $975.00 07/19/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522297
Principal investigator 1 Allergan, Inc. $4,655.25 06/24/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001841
Principal investigator 1 Gilead Sciences, Inc. $1,459.00 06/23/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522295
Principal investigator 1 Allergan, Inc. $900.50 06/15/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001839
Principal investigator 1 Gilead Sciences, Inc. $975.00 06/14/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522293
Principal investigator 1 Allergan, Inc. $390.00 06/08/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001837
Principal investigator 1 Gilead Sciences, Inc. $1,950.00 05/26/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522289
Principal investigator 1 Gilead Sciences, Inc. $3,375.00 05/26/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522291
Principal investigator 1 PFIZER INC. $5,694.00 05/22/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832804667
Principal investigator 1 Gilead Sciences, Inc. $1,368.00 05/19/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522287
Principal investigator 1 Gilead Sciences, Inc. $40.00 05/17/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522279
Principal investigator 1 Gilead Sciences, Inc. $975.00 05/17/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522281
Principal investigator 1 Gilead Sciences, Inc. $975.00 05/17/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522283
Principal investigator 1 Gilead Sciences, Inc. $975.00 05/17/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522285
Principal investigator 1 Allergan, Inc. $253.50 05/07/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001831
Principal investigator 1 Allergan, Inc. $975.00 05/07/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001833
Principal investigator 1 Allergan, Inc. $1,170.00 05/07/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001835
Principal investigator 1 Allergan, Inc. $2,923.75 05/01/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001829
Principal investigator 1 Gilead Sciences, Inc. $14,854.00 04/26/2021 Covered Recipient Teaching Hospital
Rush University Medical Center
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects with Primary Sclerosing Cholangitis No dispute reported 06/30/2026 803522277
Principal investigator 1 Allergan, Inc. $1,486.50 04/09/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001827
Principal investigator 1 Allergan, Inc. $4,460.25 03/17/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001821
Principal investigator 1 Allergan, Inc. $338.00 03/17/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001823
Principal investigator 1 Allergan, Inc. $676.00 03/17/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001825
Principal investigator 1 Allergan, Inc. $2,925.00 02/23/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001819
Principal investigator 1 Allergan, Inc. $2,090.00 02/19/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001815
Principal investigator 1 Allergan, Inc. $3,277.50 02/19/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001817
Principal investigator 1 PFIZER INC. $13,650.00 02/05/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
A PHASE 2 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBOCONTROLLED DOSERANGING DOSEFINDING PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF06865571 DGAT2I ALONE AND WHEN COADMINISTERED WITH PF05221304 ACCI IN ADULT PARTICIPANTS WITH BIOPSYCONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3 No dispute reported 06/30/2026 832734704
Principal investigator 1 Allergan, Inc. $3,900.00 02/01/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001813
Principal investigator 1 Allergan, Inc. $1,121.00 01/25/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 789001811
Principal investigator 1 Allergan, Inc. $1,596.00 01/21/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001809
Principal investigator 1 Allergan, Inc. $780.00 01/19/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001805
Principal investigator 1 Allergan, Inc. $150.00 01/19/2021 Covered Recipient Teaching Hospital
RUSH UNIVERSITY MEDICAL CENTER
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789001807